Industrial Psychiatry Journal

: 2018  |  Volume : 27  |  Issue : 1  |  Page : 87--91

25 Hydroxyvitamin D levels, quality of life, and disability in long-standing patients of somatization

Shruti Srivastava, Manjeet Singh Bhatia, Priyanka Gautam 
 Department of Psychiatry, Guru Teg Bahadur Hospital, University College of Medical Sciences, New Delhi, India

Correspondence Address:
Dr. Shruti Srivastava
Professor (Psychiatry), Department of Psychiatry, Guru Teg Bahadur Hospital, University College of Medical Sciences, Dilshad Garden, New Delhi - 110 095


Introduction: Somatization disorder is a debilitating condition, in which patients have multiple physical complaints with no explained cause and no relief even after consultations. Aim: The present study examined the association of 25-hydroxyvitamin D (25[OH]D) levels, quality of life, disability, and symptom profile in long standing with somatization disorder. Methods: One-hundred three patients of somatization disorder suffering for ≥2 years, visiting psychiatry outpatient clinic during two consecutive summer season (April to June) of 2015–2016 were recruited. Symptom profile was studied using Patient-Health-Questionnaire (PHQ-15) items (somatic symptoms), PHQ-9 items (depressive symptoms), Generalized Anxiety Disorder-7 (GAD-7) item (anxiety symptoms).quality of life was assessed using the World Health Organization Quality of Life BREF 26 item, and disability measure was World Health Organization Disability Assessment Schedule (WHODAS) 2.0. 25(OH) D levels were estimated using chemiluminescence binding assay. Results: The poor quality of life in somatization disorder was significantly associated with disability, symptom profile using PHQ-15, PHQ-9, and GAD-7. 25(OH)D levels were deficient in 56.31% of the study population. Conclusion: The high somatic symptom severity in majority of patients suffering from somatization disorder needs more attention from psychiatrists across cultures so that functional status and quality of life can be improved. Routine estimation of Vitamin D levels and correction of its deficiency may bring about symptomatic relief at an early stage, thereby reducing the morbidity associated with the disorder.

How to cite this article:
Srivastava S, Bhatia MS, Gautam P. 25 Hydroxyvitamin D levels, quality of life, and disability in long-standing patients of somatization.Ind Psychiatry J 2018;27:87-91

How to cite this URL:
Srivastava S, Bhatia MS, Gautam P. 25 Hydroxyvitamin D levels, quality of life, and disability in long-standing patients of somatization. Ind Psychiatry J [serial online] 2018 [cited 2019 Jun 16 ];27:87-91
Available from:

Full Text

Somatization disorder is a clinical condition, in which patients have multiple physical complaints with no explained cause and no relief even after consulting a number of physicians.[1] It is a disabling condition,[2] commonly presenting in general hospital clinics, with point prevalence as high as 10%–16%.[3],[4]

Somatization disorder causes more functional impairment than physical as compared to other medical disorders.[2],[5] Depressive and anxiety symptoms are commonly associated with somatization disorder and lead to disability.[2],[6] Somatization disorders are characterized by frequent use of medical services with poor response to treatment, follow a chronic course, cause significant disability, caregiver burden,[5],[6],[7],[8] and poor quality of life.[9],[10] There are very few studies on pain disorders that had assessed the response to Vitamin D supplementation in a small sample of patients.[11],[12] The present study was undertaken to overcome the lacunae in the existing literature on clinically relevant aspects of somatization disorder. Therefore, the present study was carried out to examine 25-hydroxyvitamin D (25[OH]D) levels, quality of life, disability and symptom profile in long-standing patients with somatization disorder.


This cross-sectional study was carried out in the psychiatry department of a tertiary care hospital in the capital city of Delhi. Patients between age group 18 and 60 years with multiple somatic complaints and on treatment for two or more years were screened. Those fulfilling the diagnostic criteria of somatization disorder, according to the International Classification of Diseases, tenth revision, Diagnostic criteria for Research and those who were willing to participate in the study, were recruited. The study was completed over a period of two consecutive summer seasons (April to June) of 2015–2016. Those patients with comorbid significant, unstable medical disorder or surgical illness, pregnancy, current substance use, and psychotic disorders were excluded from the study. One hundred and eighty patients were initially screened. A total of 67 patients were excluded due to medical or surgical problems and 10 patients refused consent. Finally, 103 patients were included in the study protocol which was approved by the Institutional Ethics Committee.


Sociodemographic pro forma: The sociodemographic details of the patients who gave written informed consent were recorded using a semi-structured pro formaKuppuswamy's socioeconomic status scale: The socioeconomic status was assessed using Kuppuswamy's socioeconomic status scale.[13] It includes the following three parameters: education status of head of family, occupation of head of family, and monthly family incomeWorld Health Organization Quality of Life (WHOQOL–BREF) is a 26 item tool used to assess quality of life in four domains: Physical, psychological, social and environmental and has been validated cross culturally and in Indian population [14],[15],[16]World Health Organization Disability Assessment Schedule (WHODAS) 2.0 is a practical, generic assessment instrument used to measure health and disability in clinical practice. WHODAS 2.0 assesses the level of functioning in six domains of life i.e., cognition, mobility, self-care, getting along, life activities, and participation. Test–retest reliability of WHODAS 2.0 is 0.98 at overall level [17]Patient-Health-Questionnaire (PHQ-15) is a somatic symptoms severity scale. It screens for 15 somatic symptoms that account for more than 90% of the physical complaints reported in the outpatient setting. The PHQ-15 is a valid measure in different healthcare settings. It has 15 items, each of which is scored 0–2, providing a minimum score of 0 and a maximum score of 30[18]PHQ-9 is a very specific, sensitive, and validated tool for screening of depression. It has nine items, each of which is scored 0–3, providing a minimum score of 0 and a maximum score of 27[19]Generalized Anxiety Disorder-7 (GAD-7) was initially developed to screen GAD. It is also reported to have good sensitivity and specificity as a screening instrument for other anxiety disorders i.e., panic, social anxiety, and posttraumatic stress disorder and has also been validated in these conditions. It has seven items, each of which is scored 0–3, providing a minimum score of 0 and a maximum score of 21[20]25(OH)D levels were carried out by chemiluminescence binding assay using Elecsys, 2010, Roche (Germany), Diagnostics on a fasting sample. The 25(OH)D levels were categorized as: deficient <20 ng/ml, insufficient 21–29 ng/ml, sufficient 30–100 ng/ml according to clinical guidelines.[21]

Statistical analysis

The analysis was done using the Statistical Package for the Social Sciences for windows, Version 20.0 (IBM SPSS Inc., Chicago, IL) to analyze the data. Descriptive statistics were used for sociodemographic data. Vitamin D levels, quality of life, disability was assessed using mean and standard deviation (SD) in all the four domains: physical, psychological, social and environmental of WHOQOL–BREF and general disability scores on WHODAS. Pearson correlation was applied to correlate the scores of WHOQOL–BREF in four domains, Vitamin D levels, WHODAS 2.0 general disability scores, the somatic symptoms severity scores (PHQ-15), depressive symptoms scores (PHQ-9), and anxiety symptoms score (GAD-7).


Sociodemographic statistics revealed that there were six males (5.82%) and 97 females (94.16%); mean (SD) age was 43.69 (±10.01) years. Nearly 49 (47.57%) were illiterate, 91 (88.34%) married, and 84 (81.55%) were homemakers. On socioeconomic status scale, 3 (2.9%) patients belonged to upper status, 56 (54.4%) to upper middle class, 22 (21.4%) to the upper lower, 20 (19.4%) to the lower middle, and 2 (1.9%) to the lower socioeconomic class. Seventy-eight patients (75.72%) belonged to urban background, and 25 (24.27%) were from rural area. Mean duration of illness of Somatization Disorder was 4.9 years.

Among the participants, 58 patients were deficient in 25(OH) D levels (<20 ng/ml), insufficient in 26 patients (21–29 ng/ml), and sufficient in 19 patients (30–100 ng/ml) as shown in [Table 1].{Table 1}

On PHQ-15, only 18 patients had somatic symptoms in minimal to low levels as noted. Twenty-nine patients had medium level of somatic symptoms, and 53 patients had severe somatic symptoms. Mean scores on PHQ-15, PHQ-9, and GAD-7 are given in [Table 2].{Table 2}

Mean score for all the four domain scores of WHOQOL–BREF were as follows: the mean score of physical health domain was 18.22 (SD = 6.22), mean score of psychological health domain was 15.52 (SD = 4.83), mean score of social domain was 8.45 (SD = 2.77) and that of environment domain was 22. 13 (SD = 5.51) [Table 3]. Disability assessment using WHODAS 2.0 revealed mean disability score of 1.88 (SD = 0.700).{Table 3}

[Table 4] shows the correlation of WHOQOL–BREF scores and WHODAS 2.0 with clinical symptoms variables. Statistically significant negative correlation was found between all the four domains physical, psychological, social and environment with the symptom profile on PHQ-15 (somatic symptoms), PHQ-9 (depressive symptoms), and GAD-7 (anxiety symptoms). Disability scores had statistically significant positive correlation with PHQ-15 (somatic symptoms), PHQ-9 (depressive symptoms), and GAD-7 (anxiety symptoms). No correlation was found between 25(OH)D levels, quality of life domains, and disability scores.{Table 4}


The results of our study revealed that poor quality of life is significantly associated with disability and clinical symptoms in somatization disorder. In this study, most of the patients were married females. The severity of somatic symptoms, depression, and anxiety were very significant even after years of treatment. Somatization disorders follow a chronic course. The treatment response is poor and is associated with poor quality of life and considerable disability.[22] A randomized controlled trial of brief training in the assessment and treatment of somatization in primary care has earlier shown that the overall self-reported health changes in patients with Somatization were small during 1-year follow-up.[23] Training of physicians was associated with no significant improvements in satisfaction with care. No statistically significant effect was found with regard to patients' physical function, quality of life, disability days, or somatization after 1-year follow-up.[23]

Severe somatic symptoms were recorded in 51.45% of the patients in our study. Correlation analysis has shown that somatic symptoms, anxiety, and depressive symptoms independently correlate negatively with quality of life and positively with disability scores. Earlier studies by Kushwaha et al.[6] using the Indian Disability Evaluation and assessment scale and Chadda et al.[22] using Global Assessment of Functioning and Dysfunctional analysis Questionnaire have shown similar results that the functional impairment and disability in these patients are significant. Symptom severity remains the major factor in contributing to disability in somatization disorder. Majority of the patients had comorbid anxiety and depressive symptoms which may also contribute significantly to functional impairment.

Estimation of 25(OH)D levels revealed deficient levels in 56.31% of our study population, who were then advised to take Vitamin D (cholecalciferol) 60,000 IU once a week for 3 months.[24] All the patients were counseled for daily sunlight exposure for ½ h during morning hours of 11:00 AM–2:00 PM in the afternoon. In a recent compilation of data from several Indian studies, Vitamin D deficiency ranged from 34% to 100% in different regions across several population groups from India.[25] Endocrine society Clinical Practice Guidelines recommend minimum daily allowances of Vitamin D which are as follows: infants and children (0–1 year) 400 IU/day, children above 1 year and adults (19–50 years, 50–70 years) 600 IU/day, adults (70 years and above) require at least 800 IU/day.[21]

Adequate sunlight exposure, food fortification, consumption of animal foods, and supplementation are the strategies highlighted to overcome Vitamin D deficiency in South Asian population.[26] Although we could not establish any correlation between 25(OH)D levels and quality of life or disability, a longitudinal study needs to be conducted to find out the effect of Vitamin D supplementation in somatization disorder.

The somatization disorders remain at low-priority area of research in psychiatry.[2] The impact of Vitamin D levels on the symptom profile of psychiatric disorders has been scarcely studied. In a previous pilot study carried out by the authors in the year 2013 on psychiatry outpatients (n = 120) from Delhi, 92 patients (82.14%) had Vitamin D deficiency.[27] Recently, a study had found severe deficiency in therapy-refractive schizophrenia.[28]


Somatization disorder runs a chronic course with significant effect on quality of life and leads to disability. 25(OH)D levels are found deficient in about half of the study sample. This is one of few studies which had correlated quality of life and disability with somatic, anxiety, and depressive symptoms. To the best of the knowledge of authors, this is the first study that has evaluated 25(OH)D levels in long-standing patients of somatization disorder. The high somatic symptom severity in majority of patients needs more attention from psychiatrists across cultures so that functional status and quality of life can be improved. Routine estimation of Vitamin D levels and correction of its deficiency may bring about symptomatic improvement in the patients at an early stage, thereby reducing the morbidity.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.


1Allen LA, Gara MA, Escobar JI, Waitzkin H, Silver RC. Somatization: A debilitating syndrome in primary care. Psychosomatics 2001;42:63-7.
2Bass C, Peveler R, House A. Somatoform disorders: Severe psychiatric illnesses neglected by psychiatrists. Br J Psychiatry 2001;179:11-4.
3Maharaj R, Alexander C, Bridglal CH, Edwards A, Mohammed H, Rampaul T, et al. Somatoform disorders among patients attending walk-in clinics in Trinidad: Prevalence and association with depression and anxiety. Ment Health Fam Med 2013;10:81-8.
4de Waal MW, Arnold IA, Eekhof JA, van Hemert AM. Somatoform disorders in general practice: Prevalence, functional impairment and comorbidity with anxiety and depressive disorders. Br J Psychiatry 2004;184:470-6.
5Harris AM, Orav EJ, Bates DW, Barsky AJ. Somatization increases disability independent of comorbidity. J Gen Intern Med 2009;24:155-61.
6Kushwaha V, Sinha Deb K, Chadda RK, Mehta M. A study of disability and its correlates in somatization disorder. Asian J Psychiatr 2014;8:56-8.
7van der Leeuw G, Gerrits MJ, Terluin B, Numans ME, van der Feltz-Cornelis CM, van der Horst HE, et al. The association between somatization and disability in primary care patients. J Psychosom Res 2015;79:117-22.
8Smith GR Jr., Monson RA, Ray DC. Patients with multiple unexplained symptoms. Their characteristics, functional health, and health care utilization. Arch Intern Med 1986;146:69-72.
9Nickel R, Hardt J, Kappis B, Schwab R, Egle UT. Determinants of quality of life in patients with somatoform disorders with pain as main symptom – The case for differentiating subgroups. Z Psychosom Med Psychother 2010;56:3-22.
10Sheehan B, Lall R, Bass C. Does somatization influence quality of life among older primary care patients? Int J Geriatr Psychiatry 2005;20:967-72.
11Wepner F, Scheuer R, Schuetz-Wieser B, Machacek P, Pieler-Bruha E, Cross HS, et al. Effects of Vitamin D on patients with fibromyalgia syndrome: A randomized placebo-controlled trial. Pain 2014;155:261-8.
12von Känel R, Müller-Hartmannsgruber V, Kokinogenis G, Egloff N. Vitamin D and central hypersensitivity in patients with chronic pain. Pain Med 2014;15:1609-18.
13Gururaj MS, Maheshwaran R. Kuppuswamy's socio-economic status scale – A revision of income parameter for 2014. Int J Recent Trends Sci Tech 2014;11:1-2.
14Agnihotri K, Awasthi S, Chandra H, Singh U, Thakur S. Validation of WHO QOL-BREF instrument in Indian adolescents. Indian J Pediatr 2010;77:381-6.
15Skevington SM, Lotfy M, O'Connell KA; WHOQOL Group. The World Health Organization's WHOQOL-BREF quality of life assessment: Psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res 2004;13:299-310.
16Srivastava S, Bhatia MS, Thawani R, Jhanjee A. Quality of life in patients with obsessive compulsive disorder: A longitudinal study from India. Asian J Psychiatr 2011;4:178-82.
17World Health Organization. Measuring health and disability. In: Üstün TB, Kostanjsek N, Chatterji S, Rehm J, editors. Manual for WHO Disability Assessment Schedule WHODAS 2.0. Geneva: WHO; 2010.
18Kroenke K, Spitzer RL, Williams JB. The PHQ-15: Validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 2002;64:258-66.
19Kroenke K, Spitzer RL, Williams JB, Löwe B. The patient health questionnaire somatic, anxiety, and depressive symptom scales: A systematic review. Gen Hosp Psychiatry 2010;32:345-59.
20Kroenke K, Spitzer RL, Williams JB, Monahan PO, Löwe B. Anxiety disorders in primary care: Prevalence, impairment, comorbidity, and detection. Ann Intern Med 2007;146:317-25.
21Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of Vitamin D deficiency: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911-30.
22Chadda RK, Bhatia MS, Shome S, Thakur KN. Psychosocial dysfunction in somatising patients. Br J Psychiatry 1993;163:510-3.
23Rosendal M, Olesen F, Fink P, Toft T, Sokolowski I, Bro F. A randomized controlled trial of brief training in the assessment and treatment of somatization in primary care: Effects on patient outcome. Gen Hosp Psychiatry 2007;29:364-73.
24Sinha A, Cheetham TD, Pearce SH. Prevention and treatment of Vitamin D deficiency. Calcif Tissue Int 2013;92:207-15.
25Ritu G, Gupta A. Vitamin D deficiency in India: Prevalence, causalities and interventions. Nutrients 2014;6:729-75.
26Akhtar S. Vitamin D status in South Asian populations-risks and opportunities. Crit Rev Food Sci Nutr 2016;56:1925-40.
27Bhatia MS, Kaur J, Rathi A, Srivastava S. Vitamin D deficiency among psychiatric outpatients. Delhi Psychiatry J 2014;17:113-6.
28Bogers JP, Bostoen T, Broekman TG. Low levels of Vitamin D poorly responsive to daylight exposure in patients with therapy-resistant schizophrenia. Nord J Psychiatry 2016;70:262-6.